Potential of Stem Cells and CART as a Potential Polytherapy for Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunology
• Pulmonology

Background:

• Small cell lung cancer (SCLC) presents significant treatment challenges due to incomplete understanding of its etiology, antitumor immunity, and microenvironment-driven resistance.
• Chronic obstructive pulmonary disease (COPD) shares common pathogenetic factors with lung cancer and is a known risk factor for SCLC, highlighting the need for integrated management strategies.

Purpose of the Study:

• To review the current understanding of SCLC etiology and pathogenesis.
• To analyze the efficacy of existing SCLC treatments and evaluate chimeric antigen receptor T cells (CART) therapy potential.
• To explore the relationship between SCLC and COPD, including the role of the endothelium in COPD pathogenesis.

Main Methods:

• Literature review of SCLC etiology, pathogenesis, and treatment modalities.
• Critical analysis of current therapeutic strategies for SCLC.
• Evaluation of chimeric antigen receptor T cells (CART) therapy in the context of SCLC and COPD.

Main Results:

• Fragmentary knowledge exists regarding SCLC causes and resistance mechanisms, hindering new diagnostic and therapeutic development.
• COPD is identified as a risk factor for SCLC, necessitating focused research on prevention, diagnosis, and treatment in this patient group.
• Current SCLC treatments have limitations, and CART therapy shows potential but requires optimization.

Conclusions:

• There is an urgent need for enhanced understanding of SCLC pathogenesis and antitumor immunity to improve treatment outcomes.
• Investigating the links between SCLC and COPD, alongside endothelial dysfunction, is crucial for developing effective interventions.
• A novel approach is proposed to enhance the efficacy of CART therapy for SCLC, offering a promising avenue for future research and clinical application.